Vectibix @ ARI

Discussion in 'Amgen' started by usedtowork@ARI, Jan 11, 2010 at 7:09 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    wonder if I be around long enough to see manager make behinds of themselves, I am sure it will be amusing, not to the poor souls that are still there behind, because you know it's a given, mangers will make fools of themselves
     

  2. Anonymous

    Anonymous Guest

    WTF
     
  3. Anonymous

    Anonymous Guest

    I thought that was a killer phrase, if not is should be
     
  4. Anonymous

    Anonymous Guest

    pay it back ashole
     
  5. Anonymous

    Anonymous Guest

    just wait to see how making two products will be the downfall of ARI
     
  6. Anonymous

    Anonymous Guest


    I keep wondering if ARI is the ONLY place that everyone dislikes. Does that mean all other plants run flawlessly?
     
  7. Anonymous

    Anonymous Guest

    No it means everyone knows you have real issues there and there is a real problem at that facility. Wake up Amgen and take a good look at a bad investment.
     
  8. Anonymous

    Anonymous Guest

    Can’t wait for their first change over that site couldn’t change a diaper!
     
  9. Anonymous

    Anonymous Guest

    Can’t wait for their first change over that site couldn’t change a diaper!
     
  10. Anonymous

    Anonymous Guest

    Hire more directors
     
  11. Anonymous

    Anonymous Guest

    Amgen is under department of justice investigation for illegal criminal and civil acts. They have some serious problems going on. They may be able to treat us employees like shit, However, I don't think they are going to push around the government. Every illegal and unethical act is going to come back to them. Amgen is a cesspool of eggregious corporate behavior starting at the top. Look how much KS makes And how bad they treat us. They can lie and make stuff up about you just to get you fired. They don't care either because they know the arbitration is bullshit and employees have no recourse. Maybe the possibility of Jailtime will change a few behaviors around here. This is all in the public filings and it's not pretty. You can't keep treating people like shit and expect good results.
     
  12. Anonymous

    Anonymous Guest

    Don't worry...There is no need for additional supply of Vectibix...Didn't you read the clinical data report. Vectibix will continue it's downward spiral....And Prolia, is not far behind.
     
  13. Anonymous

    Anonymous Guest

    I am begining to believe that this was just a pacifier

     
  14. Anonymous

    Anonymous Guest

    Amgen's Vectibix fails head-and-neck cancer trialBY Reuters
    — 10:54 AM ET 08/11/2010
    * Vectibix fails to prolong survival in late-stage study

    * Fails secondary goals among head, neck cancer patients

    shares fall 3.8 percent (Adds side effects, details on cancer, updates shares)

    By Ransdell Pierson

    NEW YORK, Aug 11 (Reuters) - Amgen Inc's (AMGN



    Vectibix colon cancer drug has proven to be ineffective as a first-line treatment for head and neck cancer in a late-stage study, posing another setback for the world's biggest biotechnology company as it struggles to boost revenue.

    Vectibix, when combined with chemotherapy, failed to prolong survival among patients with squamous cell head and neck cancer, compared with chemotherapy alone -- thereby failing in the the primary goal of the study.
    The median survival period for those taking Vectibix was 11.1 months in the 658-patient trial, versus nine months for chemotherapy alone. But the difference was not deemed statistically significant.



    The drug was associated with numerical improvements in shrinking tumors and of prolonging the time without a worsening of symptoms, but the study was not designed to test those secondary goals for statistical significance.

    The most common side effects in patients taking Vectibix plus chemotherapy included nausea and rash.

    Oral head and neck cancer is the sixth most common cancer in the world, with more than 400,000 new cases diagnosed each year. Survival is highly dependent on the stage at which it is diagnosed.


    Vectibix had second-quarter sales of $72 million, making it a fairly small product for Amgen




    One of the company's biggest products is $2.5 billion-a-year anemia drug Aranesp, whose sales continue to decline amid concerns about safety of its class of medicines.

    Analysts once heralded Vectibix as a potential blockbuster product, but it has yet to live up to its potential as a growth driver for Amgen



    Vectibix, an antibody that blocks a protein receptor called epidermal growth factor, was approved by U.S. regulators in 2006 as a stand-alone treatment for patients with metastatic colon cancer.

    It competes with a similar colon-cancer drug called Erbitux sold by Bristol-Myers Squibb Co's
    and Eli Lilly and Co (LLY




    Erbitux is also approved to treat head and neck cancer. (Reporting by Ransdell Pierson; Editing by Maureen Bavdek and Steve Orlofsky)
     
  15. Anonymous

    Anonymous Guest

    Vectibix and Enbrel sales will be half of what they are today in three years. ARI will be shut down before then and its few dwindling products will be outsourced.
     
  16. Anonymous

    Anonymous Guest

    This is just hogwash

    Our weekend manager says that sales of Vectibix will jump 30X fold in the next year.












     
  17. Anonymous

    Anonymous Guest

    And you trust ARI Management??? Put the kool-aide down.
     
  18. Anonymous

    Anonymous Guest

    Can you spell "brainwash"
     
  19. Anonymous

    Anonymous Guest

    My boss is panic mode


     
  20. Anonymous

    Anonymous Guest

    You are an inept drone